Results 131 to 140 of about 16,284 (167)
Some of the next articles are maybe not open access.
BioDrugs, 1999
Recombinant factor VIIa is a preparation of activated coagulation factor VII (factor VIIa) that is produced by recombinant DNA technology. The drug expedites blood coagulation without the need for factors VIII and IX in patients with haemophilia. Indicators of activation of systemic coagulation of blood were unchanged and mean prothrombin times and ...
C J, Dunn, C M, Spencer
openaire +2 more sources
Recombinant factor VIIa is a preparation of activated coagulation factor VII (factor VIIa) that is produced by recombinant DNA technology. The drug expedites blood coagulation without the need for factors VIII and IX in patients with haemophilia. Indicators of activation of systemic coagulation of blood were unchanged and mean prothrombin times and ...
C J, Dunn, C M, Spencer
openaire +2 more sources
Synthetic substrates for human factor VIIa and factor VIIa-tissue factor
Biochemistry, 1993A series of 100 tripeptide fluorogenic substrates has been synthesized. These substrates contain Arg in the P1 position, various amino acids in the P2 and P3 positions, and different 6-amino-1-naphthalenesulfonamides (ANSN) as the detecting group (P').
S, Butenas, N, Ribarik, K G, Mann
openaire +2 more sources
Emergency Medicine, 2004
Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that
openaire +2 more sources
Human coagulation factor (F) VII is a single chain protease that circulates in the blood as a weakly active zymogen at concentrations of approximately 10 nmol/L. When converted to the active 2 chain form (FVIIa), it is a powerful initiator of haemostasis. Recombinant factor VIIa (rFVIIa, eptacog alfa, NovoSeven) is a genetically engineered product that
openaire +2 more sources
Factor VIIa in the treatment of haemophilia
Blood Coagulation & Fibrinolysis, 1990Recombinant FVIIa is being developed for treatment of haemophiliacs with antibodies against FVIII/FIX. rFVIIa was shown to be haemostatically active in haemophilia A and B dogs as well as in 20 haemophilia patients (one haemophilia B and 19 haemophilia A patients). Thirteen patients were treated for life-threatening bleedings and nine at surgery (dose:
openaire +2 more sources
Experiences with Recombinant Factor VIIa in Hemophiliacs
1991Treatment of hemophiliacs with antibodies against factor VIII and factor IX is a matter of major concern in hemophilia care. Although a number of sophisticated methods for removal of antibodies have been designed, such procedures are suitable only in life-threatening situations since they are complicated and expensive.1, 2 Much effort has been focused ...
openaire +2 more sources
AACN Advanced Critical Care, 2007
Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest.
openaire +1 more source
Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest.
openaire +1 more source